Compare PRGO & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRGO | TNDM |
|---|---|---|
| Founded | 1887 | 2006 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2013 | 2013 |
| Metric | PRGO | TNDM |
|---|---|---|
| Price | $12.27 | $18.03 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 19 |
| Target Price | $19.33 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 2.2M | 1.5M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 10.28% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $800,000.00 | ★ $1,014,736,000.00 |
| Revenue This Year | N/A | $8.11 |
| Revenue Next Year | $1.02 | $11.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 7.93 |
| 52 Week Low | $9.23 | $10.00 |
| 52 Week High | $28.44 | $29.65 |
| Indicator | PRGO | TNDM |
|---|---|---|
| Relative Strength Index (RSI) | 61.66 | 38.92 |
| Support Level | $12.17 | $17.79 |
| Resistance Level | $15.08 | $21.68 |
| Average True Range (ATR) | 0.47 | 1.17 |
| MACD | 0.04 | -0.06 |
| Stochastic Oscillator | 76.52 | 10.41 |
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo has divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two-thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.